Company’s 36-month beta value is 2.10.Analysts have differing opinions on the stock, with 4 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CLSD is 64.29M, and currently, short sellers hold a 1.21% ratio of that floaft. The average trading volume of CLSD on February 20, 2025 was 241.27K shares.
CLSD) stock’s latest price update
The stock price of Clearside Biomedical Inc (NASDAQ: CLSD) has dropped by -1.96 compared to previous close of 1.05. Despite this, the company has seen a fall of -0.06% in its stock price over the last five trading days. globenewswire.com reported 2025-02-20 that ALPHARETTA, Ga., Feb. 20, 2025 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), reported that Arctic Vision’s New Drug Application (NDA) for ARCATUS® for the treatment of uveitic macular edema (UME) has been formally accepted for review by the Center for Drug Evaluation of China National Medical Products Administration. The NDA submission is supported by positive topline results from Arctic Vision’s Phase 3 UME clinical trial in China.
CLSD’s Market Performance
Clearside Biomedical Inc (CLSD) has experienced a -0.06% fall in stock performance for the past week, with a 11.64% rise in the past month, and a 3.98% rise in the past quarter. The volatility ratio for the week is 5.04%, and the volatility levels for the past 30 days are at 6.09% for CLSD. The simple moving average for the past 20 days is 2.46% for CLSD’s stock, with a -8.48% simple moving average for the past 200 days.
Analysts’ Opinion of CLSD
Many brokerage firms have already submitted their reports for CLSD stocks, with Chardan Capital Markets repeating the rating for CLSD by listing it as a “Buy.” The predicted price for CLSD in the upcoming period, according to Chardan Capital Markets is $6 based on the research report published on August 21, 2024 of the previous year 2024.
Oppenheimer, on the other hand, stated in their research note that they expect to see CLSD reach a price target of $5. The rating they have provided for CLSD stocks is “Outperform” according to the report published on June 25th, 2024.
Wedbush gave a rating of “Outperform” to CLSD, setting the target price at $9 in the report published on December 15th of the previous year.
CLSD Trading at 5.07% from the 50-Day Moving Average
After a stumble in the market that brought CLSD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -51.44% of loss for the given period.
Volatility was left at 6.09%, however, over the last 30 days, the volatility rate increased by 5.04%, as shares surge +8.92% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading unchanged at present.
During the last 5 trading sessions, CLSD rose by +0.97%, which changed the moving average for the period of 200-days by -21.21% in comparison to the 20-day moving average, which settled at $1.0052. In addition, Clearside Biomedical Inc saw 8.36% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CLSD starting from Chong Ngai Hang Victor, who purchase 36,500 shares at the price of $1.00 back on Nov 01 ’24. After this action, Chong Ngai Hang Victor now owns 100,000 shares of Clearside Biomedical Inc, valued at $36,500 using the latest closing price.
Chong Ngai Hang Victor, the Chief Medical Officer of Clearside Biomedical Inc, purchase 23,500 shares at $1.06 during a trade that took place back on Jun 24 ’24, which means that Chong Ngai Hang Victor is holding 63,500 shares at $24,910 based on the most recent closing price.
Stock Fundamentals for CLSD
Current profitability levels for the company are sitting at:
- -3.2 for the present operating margin
- 0.99 for the gross margin
The net margin for Clearside Biomedical Inc stands at -4.14. The total capital return value is set at -1.05.
Based on Clearside Biomedical Inc (CLSD), the company’s capital structure generated -0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -24.14. The debt to equity ratio resting at -0.02. The interest coverage ratio of the stock is -2.6.
Currently, EBITDA for the company is -23.06 million with net debt to EBITDA at 0.59. When we switch over and look at the enterprise to sales, we see a ratio of 8.44. The receivables turnover for the company is 9.78for trailing twelve months and the total asset turnover is 0.26. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.49.
Conclusion
In a nutshell, Clearside Biomedical Inc (CLSD) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
